This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Prime Radiant Invests in Cellares Series D
Business growth equity investment

Prime Radiant Invests in Cellares Series D

Analysis based on 7 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The investment in Cellares is expected to accelerate the development and commercialization of cell therapies by expanding Cellares' automated manufacturing capabilities globally. This could lead to increased access to life-saving treatments and potentially lower manufacturing costs, positively impacting the biotechnology and pharmaceutical sectors. The involvement of prominent investors like BlackRock and T. Rowe Price signals strong market confidence in Cellares' IDMO model.

Biotechnology Pharmaceuticals Venture Capital
Event Summary

Cellares, an Integrated Development and Manufacturing Organization (IDMO) focused on automating cell therapy manufacturing, announced a $50 million growth equity investment from Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners. This investment brings Cellares' total Series D financing to $327 million. Prime Radiant Partners, making its inaugural investment since its 2025 launch, joins a distinguished group of existing investors including ARK Investment Management, BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., Duquesne Family Office, Baillie Gifford, Intuitive Ventures, EDBI, Gates Frontier, Liquefied natural gas, DFJ Growth, and Willett Advisors. The funding will support the next phase of Cellares' global Smart Factory buildout, including a facility under construction in Netherlands — Leiden, the Netherlands, set to be GMP-ready in 2027. Cellares currently has active programs with drug sponsors such as Bristol Myers Squibb, Cabaletta Bio, TScan Therapeutics, and ProTgen, and has significant agreements including a $380 million global manufacturing agreement with Bristol Myers Squibb and a 10-year commercial supply agreement with Cabaletta Bio.

Entities Involved
priv
Cellares
Cellares received a $50 million growth equity investment from Prime Radiant Fund SLP SICAV-RAIF, bringing its Series D financing to $327 million. This investment will support the global buildout of its Smart Factories and expansion in Europe, enhancing its ability to provide automated cell therapy manufacturing services.
Importance 100.0 Sentiment 75.0
priv
Prime Radiant Partners
Prime Radiant Partners, through its advised fund Prime Radiant Fund SLP SICAV-RAIF, made its inaugural $50 million growth equity investment in Cellares. This marks the firm's first investment since its launch in 2025 and positions it as a strategic partner for Cellares' European expansion.
Importance 90.0 Sentiment 60.0
oth
Prime Radiant Fund SLP SICAV-RAIF
Prime Radiant Fund SLP SICAV-RAIF, advised by Prime Radiant Partners, invested $50 million in Cellares' Series D financing. This is the fund's first investment and contributes to Cellares' global manufacturing expansion.
Importance 90.0 Sentiment 60.0
per
Fabian Gerlinghaus
Fabian Gerlinghaus, Co-Founder and CEO of Cellares, highlighted the strategic importance of Prime Radiant's investment for Cellares' European expansion and the overall strength of the platform.
Importance 80.0 Sentiment 70.0
per
Walid Gardezi
Walid Gardezi, Co-Founder and Partner at Prime Radiant Partners, emphasized Cellares' role in building essential manufacturing infrastructure for cell therapy and Prime Radiant's commitment to supporting Cellares' European expansion.
Importance 70.0 Sentiment 60.0
per
Giovanni Fazio
Giovanni Fazio, Co-Founder and Partner at Prime Radiant Partners, expressed conviction in the Cellares platform and the future of cell and gene therapy manufacturing, marking this as the first investment in a distinctive portfolio.
Importance 60.0 Sentiment 60.0
per
Peter Soelkner
Peter Soelkner, Co-Founder and Partner at Prime Radiant Partners, expressed excitement about partnering with Cellares and its potential to fundamentally change market dynamics for cell therapies.
Importance 60.0 Sentiment 60.0
priv
Duquesne Family Office
Duquesne Family Office is an existing investor in Cellares' Series D financing, supporting the company's expansion.
Importance 20.0 Sentiment 10.0
priv
Intuitive Ventures
Intuitive Ventures is an existing investor in Cellares' Series D financing, demonstrating continued support for the company.
Importance 20.0 Sentiment 10.0
oth
Gates Frontier
Gates Frontier is an existing investor in Cellares' Series D financing, showing continued investment in the company.
Importance 20.0 Sentiment 10.0
priv
DFJ Growth
DFJ Growth is an existing investor in Cellares' Series D financing, contributing to the total Series D amount.
Importance 20.0 Sentiment 10.0
priv
Willett Advisors
Willett Advisors is an existing investor in Cellares' Series D financing, demonstrating continued support for the company.
Importance 20.0 Sentiment 10.0
priv
Liquefied natural gas
Liquefied natural gas is an existing investor in Cellares' Series D financing, supporting the company's expansion.
Importance 20.0 Sentiment 10.0
priv
ARK Investment Management
ARK Investment Management is an existing investor in Cellares' Series D financing, demonstrating continued support for the company's growth.
Importance 20.0 Sentiment 10.0
priv
Baillie Gifford
Baillie Gifford is an existing investor in Cellares' Series D financing, contributing to the total Series D amount.
Importance 20.0 Sentiment 10.0
+ 16 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.